In approving Evista (raloxifene) for breast cancer prevention, the FDA offers a wonderful choice to women with osteoporosis and a high risk of breast cancer. For others (and their doctors) it may be a challenge to sort out the risks and benefits.
To refresh your memory: In June 2006, results from the STAR trial showed that raloxifene prevented most breast cancer with fewer side effects than tamoxifen, while reducing the risk of fracture. But tamoxifen scored better against noninvasive breast cancers.
Two months ago, the RUTH trial linked raloxifene to an increased risk of fatal stroke.
Results Organized by Category:
Clinical Trials for Patients
For sisters of breast cancer patients, a new clinical trial examining risk factors may provide a sense of contributing to a solution.
Patient Education Materials
Quickly find reliable information about raloxifene side effects to give a concerned patient.
Posted by Cranky Aged Mama
Posted by Cranky Aged Mama
Posted by Cranky Aged Mama
